Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy

International Journal of Cancer

Volumn 121, Issue 8, 2007, Pages 1847-1856

  Bowen, Joanne M ^a,b   Gibson, Rachel J ^a,b   Tsykin, Anna ^b,c   Stringer, Andrea M ^a,b   Logan, Richard M ^b   Keefe, Dorothy M K ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c HANSON INSTITUTE   (Australia)

Author keywords

Chemotherapy; Gastrointestinal tract; Microarray; Mucositis

Indexed keywords

ATROPINE; COMPLEMENT COMPONENT C7; CYCLIN B2; CYTOKINE; CYTOKINE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; RNA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON; COMPUTER PROGRAM; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; JEJUNUM; MUCOSA INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STOMACH; UNINDEXED SEQUENCE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL CYCLE PROTEINS; COLON; FEMALE; GASTROINTESTINAL TRACT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; JEJUNUM; MUCOSITIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; SIGNAL TRANSDUCTION; STOMACH; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 34548689348     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22895     Document Type: Article

References (40)

1. Bowen JM, Gibson RJ, Cummins AG, Keefe DM. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 2006;14(7):713-31.
2. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003;18(9):1095-100.
3. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006;14(9):890-900.
4. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000;47(5):632-7.
5. Keefe DM, Gibson RJ, Hauer-Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs 2004;20(1):38-47.
6. Keefe DM. Gastrointestinal mucositis: a new biological model. Support Care Cancer 2004;12(1):6-9.
7. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2(1):21-32; discussion 35-6.
8. Sonis ST. Pathobiology of mucositis. Semin Oncol Nurs 2004;20(1):11-5.
9. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100(9 Suppl):1995-2025.
10. Bowen JM, Gibson RJ, Keefe DM, Cummins AG. Cytotoxic chemotherapy upregulate pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005;37(1):56-62.
11. Bowen JM, Gibson RJ, Cummins AG, Tyskin A, Keefe DM. Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol 2006;59(3):337-48.
12. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98(7):1531-9.
13. Trier JS. Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine. II. Electron microscopic observations. Gastroenterology 1962;43:407-24.
14. Trier JS. Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine. I. Serial observations by light microscopy. Gastroenterology 1962;42:295-305.
15. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4(4):277-84.
16. Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2007;43(3):289-300.
17. Bowen JM, Gibson RJ, Stringer AM, Chan TW, Prabowo AS, Cummins AG, Keefe DMK. Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs 2007;18(2):197-210.
18. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005;116(3):464-70.
19. Gibson R, Bowen J, Alvares A, Finnie J, Keefe D. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy, in press.
20. Wu Z, Irizarry RA. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 2005;12(6):882-93.
21. Lu Y, Liu PY, Xiao P, Deng HW. Hotelling's T2 multivariate profiling for detecting differential expression in microarrays. Bioinformatics 2005;21(14):3105-13.
22. Andoh A, Kinoshita K, Rosenberg I, Podolsky DK. Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol 2001;167(7):3887-93.
23. Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci 1997;92(4):385-9.
24. Keefe DM. The effect of cytotoxic chemotherapy on the mucosa of the small intestine PhD Thesis, Department of Medicine, University of Adelaide, Adelaide, 1998.
25. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002;20(6):1491-8.
26. Nowell S, Falany CN. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 2006;25(11):1673-8.
27. Ustundag B, Kazez A, Demirbag M, Canatan H, Halifeoglu I, Ozercan IH. Protective effect of melatonin on antioxidative system in experimental ischemia-reperfusion of rat small intestine. Cell Physiol Biochem 2000;10(4):229-36.
28. Liu S, Li J, Tao Y, Xiao X. Small heat shock protein alphaB-crystallin binds to p53 to sequester its translocation to mitochondria during hydrogen peroxide-induced apoptosis. Biochem Biophys Res Commun 2007;354(1):109-14.
29. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski K, Kamer I, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002;22(7):2283-93.
30. DeHaan RD, Yazlovitskaya EM, Persons DL. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol 2001;48(5):383-8.
31. Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T. NF-κB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. Embo J 2005;24(1):128-37.
32. Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci 2006;26(39):9996-10005.
33. Hungness ES, Luo GJ, Pritts TA, Sun X, Robb BW, Hershko D, Hasselgren PO. Transcription factors C/EBP-beta and -delta regulate IL-6 production in IL-1beta-stimulated human enterocytes. J Cell Physiol 2002;192(1):64-70.
34. Hungness ES, Pritts TA, Luo GJ, Hershko DD, Robb BW, Hasselgren PO. IL-1beta activates C/EBP-beta and delta in human enterocytes through a mitogen-activated protein kinase signaling pathway. Int J Biochem Cell Biol 2002;34(4):382-95.
35. Sonis ST. The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 2002;13(5):380-9.
36. Sonis ST, O'Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 2004;40(2):170-6.
37. Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2007;43(4):395-401.
38. Yeoh AS, Bowen JM, Gibson RJ, Keefe DM. Nuclear factor κB (NFκB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 2005;63(5):1295-303.
39. Hall PD, Benko H, Hogan KR, Stuart RK. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 1995;23(12):1256-60.
40. Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, Login G, Ymamkawa M, Moses G, Bouchard P, Hayes LL, Bedrosian C, et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 2000;36(4):373-81.